{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Imran TF"],"funding":["NIGMS"],"pagination":["e0295359"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10699593"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(12)"],"pubmed_abstract":["<h4>Background</h4>Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear.<h4>Objective</h4>The purpose of this study is to examine the effects of PCSK9 inhibit"],"journal":["PloS one"],"pubmed_title":["Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis."],"pmcid":["PMC10699593"],"funding_grant_id":["Project number: 5P20GM103652-10, Sub-Project ID: 9499"],"pubmed_authors":["Jacobson A","Bogin S","Kim S","Wu WC","Khan AA","Aspry K","Imran TF","Khalid M","Khan A","Choudhary G","Has P","Erqou S"],"additional_accession":[]},"is_claimable":false,"name":"Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.","description":"<h4>Background</h4>Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Atherosclerosis occurs due to accumulation of low-density lipoprotein cholesterol (LDL-c) in the arterial system. Thus, lipid lowering therapy is essential for both primary and secondary prevention. Proprotein convertase subtilisn/kexin type 9 (PCSK9) inhibitors (Evolocumab, Alirocumab) and small interfering RNA (siRNA) therapy (Inclisiran) have been demonstrated to lower LDL-c and ASCVD events in conjunction with maximally tolerated statin therapy. However, the degree of LDL-c reduction and the impact on reducing major adverse cardiac events, including their impact on mortality, remains unclear.<h4>Objective</h4>The purpose of this study is to examine the effects of PCSK9 inhibit","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-05T13:02:34.018Z","creation":"2024-11-06T04:59:28.894Z"},"accession":"S-EPMC10699593","cross_references":{"pubmed":["38055686"],"doi":["10.1371/journal.pone.0295359"]}}